Last reviewed · How we verify
LEO 138559
At a glance
| Generic name | LEO 138559 |
|---|---|
| Also known as | LEO 138559 is also called "temtokibart" |
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis (PHASE2)
- An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. (PHASE2)
- A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD (PHASE2)
- Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis (PHASE1)
- A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 138559 CI brief — competitive landscape report
- LEO 138559 updates RSS · CI watch RSS
- LEO Pharma portfolio CI